Reduced hazard ratio seen for disease progression or death with sotorasib-panitumumab versus standard care<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 24, 2023 (HealthDay News) — For patients with chemorefractory metastatic colorectal cancer, the KRAS G12C inhibitor sotorasib in combination with the epidermal growth factor receptor inhibitor panitumumab results in longer progression-free survival than standard treatment, according to a study published online Oct. 22 in the\u00a0New England Journal of Medicine.<\/em>\u00a0The research was published to coincide with the annual meeting of the European Society for Medical Oncology, held from Oct. 20 to 24 in Madrid.<\/p>\n Marwan G. Fakih, M.D., from the City of Hope Comprehensive Cancer Center in Duarte, California, and colleagues randomly assigned patients with chemorefractory metastatic colorectal cancer with mutated\u00a0KRAS<\/em>\u00a0G12C who had not received previous treatment with a KRAS G12C inhibitor to receive sotorasib 960 mg once daily plus panitumumab, sotorasib 240 mg once daily plus panitumumab, or the investigator’s choice of trifluridine-tipiracil or regorafenib (standard care; 53, 53, and 54 patients, respectively).<\/p>\n The researchers found that the median progression-free survival was 5.6 and 3.9 months versus 2.2 months in the 960-mg and 240-mg sotorasib-panitumumab groups, respectively, versus the standard-care group after a median follow-up of 7.8 months. The hazard ratio for disease progression or death was 0.49 and 0.58 in the 960-mg and 240-mg sotorasib-panitumumab groups, respectively, compared with the standard-care group. In the 960-mg and 240-mg sotorasib-panitumumab groups and the standard-care group, the objective response rate was 26.4, 5.7, and 0 percent, respectively. Overall, treatment-related adverse events of grade 3 or higher occurred in 35.8, 30.2, and 43.1 percent, respectively.<\/p>\n “These findings are important in the context of the poor survival outcomes associated with\u00a0KRAS<\/em>\u00a0G12C mutation in patients with colorectal cancer,” the authors write.<\/p>\n Several authors disclosed ties to pharmaceutical companies, including Amgen, which manufactures sotorasib and panitumumab and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/ins><\/p>\n